US Nuclear’s Grapheton Advancing Brain Probes to Treat Opioid Addiction
Fortunately, Grapheton’s deep brain stimulation (DBS) technology is being researched as an effective, long-term treatment for helping people with treatment-resistant addiction. Patients who undergo deep brain stimulation therapy have tiny electrodes surgically implanted in certain areas of the brain which are stimulated by pulses of electricity. The parameters of the stimulation are programmable and depend on the region of the brain, type of addiction, movement disorder pain, and patient response.
The
Grapheton has propelled the treatment even further by developing groundbreaking improvements to their deep brain stimulation probes. Current probes from other providers only last 1-5 years before requiring surgery again. Grapheton has developed a new graphene polymer
Safe Harbor Act
This press release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations, estimates and projections and, consequently, you should not rely on these forward looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results.
Investors may find additional information regarding
CONTACT:
(818) 883 7043
Email: info@usnuclearcorp.com
Abstract
Drug addiction represents a significant public health concern that has high rates of relapse despite optimal medical therapy and rehabilitation support. New therapies are needed, and deep brain stimulation (DBS) may be an effective treatment. The past 15 years have seen numerous animal DBS studies for addiction to various drugs of abuse, with most reporting decreases in drug-seeking behavior with stimulation. The most common target for stimulation has been the nucleus accumbens, a key structure in the mesolimbic reward pathway. In addiction, the mesolimbic reward pathway undergoes a series of neuroplastic changes. Chief among them is a relative hypo-functioning of the prefrontal cortex, which is thought to lead to the diminished impulse control that is characteristic of drug addiction. The prefrontal cortex, as well as other targets involved in drug addiction such as the lateral habenula, hypothalamus, insula, and subthalamic nucleus have also been stimulated in animals, with encouraging results. Although animal studies have largely shown promising results, current DBS studies for drug addiction primarily use stimulation during active drug use. More data are needed on the effect of DBS during withdrawal in preventing future relapse. The published human experience for DBS for drug addiction is currently limited to several promising case series or case reports that are not controlled. Further animal and human work is needed to determine what role DBS can play in the treatment of drug addiction.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6329833/#R52
Source:
2020 GlobeNewswire, Inc., source